News for Kyowa Kirin Co., Ltd. (4151.T)

PR NewswireTHOUSAND OAKS, Calif., April 25, 2025 Total Investment in the State to Exceed $1.4 Billion, 750 U.S. Jobs THOUSAND OAKS, Calif., April 25, 2025

PR NewswireTHOUSAND OAKS, Calif., April 11, 2025 First Global Phase 3 Trial Showing Substantial Survival Advantage Over Chemotherapy, for Patients With Pro

SAN DIEGO, April 04, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the ”œCompany”) ( KURA), a clinical-stage biopharmaceutical company committed to realizi

**media[585963]**

PR NewswireLA JOLLA, Calif. and PRINCETON, N.J., April 3, 2025 -Agreement extends one of the world's most enduring alliances for drug discovery- -Landmark

PR NewswireTHOUSAND OAKS, Calif., April 3, 2025 Breakthrough CD19+ B-Cell Targeted Therapy Delivered an 87% Reduction in the Risk of Flares Versus Placebo

**media[582624]**

PR NewswireTHOUSAND OAKS, Calif., March 13, 2025 Patients Reported Improvement in Ability to Conduct Daily Activities with Twice-Yearly Dosing*Late-Breakin

Amgen Inc (AMGN) and Kyowa Kirin Co., Ltd. have released new results from their ROCKET Phase 3 clinical trial program, evaluating rocatinlimab, a T-cell rebalan

**media[560114]**

PR NewswireTHOUSAND OAKS, Calif., March 4, 2025 THOUSAND OAKS, Calif., March 4, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of

**media[556725]**

PR NewswireTHOUSAND OAKS, Calif., March 1, 2025 Significantly Reduced Nasal Congestion, Polyp Size and Nearly Eliminated Need for Surgery Data Published in

”“ KOMET-001 registrational trial in R/R NPM1-mutant AML achieved primary endpoint ”“ ”“ Alignment reached with FDA and EMA on key aspects of the KOMET-017

**media[551505]**

PR NewswirePRINCETON, N.J., Feb. 26, 2025 PRINCETON, N.J., Feb. 26, 2025 /PRNewswire/ -- Kyowa Kirin Co., Ltd. (TSE: 4151) today announced that results of

SAN DIEGO, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the ”œCompany”) ( KURA), a clinical-stage biopharmaceutical company committed to realizin

SAN DIEGO, Feb. 07, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the ”œCompany”) ( KURA), a clinical-stage biopharmaceutical company committed to realizin

**media[533438,533439]**